Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities.
A 15-week double-blind, randomized, within-patient design was used to assess carbamazepine versus placebo as adjunctive treatment in chronic hospitalized psychiatric inpatients (predominantly schizophrenic) with EEG temporal lobe abnormalities but no clinical evidence of epilepsy. A statistically significant improvement on carbamazepine was found on all clinical rating measures used (Overall Clinical Rating, Brief Psychiatric Rating Scale, and Global Assessment). The results also appeared to be clinically significant.
D000293:Adolescent; D000328:Adult; D002220:Carbamazepine / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004569:Electroencephalography; D005260:Female; D006760:Hospitalization; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D011897:Random Allocation; D012559:Schizophrenia / Q000188:drug therapy / Q000503:physiopathology; D012565:Schizophrenic Psychology; D013702:Temporal Lobe / Q000503:physiopathology*
D002220:Carbamazepine